Nomad Power Solutions (NMAD) Current Leases (2025 - 2026)
Nomad Power Solutions (NMAD) posted Current Leases of $940775.0 for Q2 2026, up 58.0% on a QoQ basis from $595418.0 in Q4 2025.
Powered by 
Analysis
Nomad Power Solutions (NMAD) Current Leases (2025 - 2026) Analysis & Trends
Nomad Power Solutions has reported Current Leases for 2 years, with the latest figure at $940775.0 in Q2 2026.
- On a quarterly basis, Current Leases changed N/A year-over-year to $940775.0 in Q2 2026; TTM through Jun 2026 was $940775.0, a N/A change from a year earlier, with the FY2025 full-year figure at $595418.0, changed N/A from the prior year.
- Current Leases was $940775.0 for Q2 2026 at Nomad Power Solutions, up from $595418.0 in the prior quarter.
- The five-year high for Current Leases was $940775.0 in Q2 2026, with the low at $595418.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 12.38 Mn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - | 940,775.00 |